Ben Hargreaves examines why a research project in the UK could provide key insights to develop treatments against many of the most prominent diseases impacting society.
DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing.
Researchers have found that a genetic test can successfully predict whether chemotherapy would be beneficial for patients with the most common type of breast cancer – oestrogen-receptor pos